Last updated: August 1, 2026
Eskalith CR is an extended-release lithium carbonate product for maintenance treatment of bipolar disorder. Its commercial position is now legacy-oriented: Eskalith CR has no meaningful branded clinical-development program, the active-ingredient market is supplied primarily by generic lithium carbonate products, and no material patent-based exclusivity supports a branded relaunch. Clinical research continues for lithium carbonate and lithium salts, but those studies generally do not restore exclusivity for Eskalith CR.
What is Eskalith CR and what is its FDA-approved use?
Eskalith CR contains lithium carbonate in a controlled-release tablet. Lithium is a mood stabilizer approved for the treatment of manic episodes and maintenance therapy in bipolar disorder. The extended-release formulation is intended to reduce dosing frequency and produce more consistent lithium exposure than immediate-release tablets.
| Attribute |
Eskalith CR |
| Active ingredient |
Lithium carbonate |
| Dosage form |
Controlled-release oral tablet |
| Historical strengths |
450 mg tablet commonly marketed |
| Therapeutic class |
Mood stabilizer |
| Core indication |
Bipolar disorder, including manic episodes and maintenance treatment |
| FDA pathway |
505(b)(1) new drug application history |
| Current commercial status |
Legacy/discontinued branded product; generic extended-release lithium remains available |
| Primary monitoring requirement |
Serum lithium concentration, renal function, thyroid function, electrolytes |
| Main safety risks |
Lithium toxicity, renal impairment, hypothyroidism, hypercalcemia, dehydration and drug interactions |
Lithium has a narrow therapeutic index. The FDA labeling requires clinical monitoring because toxicity can occur near therapeutic concentrations. Risk increases with dehydration and with interacting medicines such as thiazide diuretics, nonsteroidal anti-inflammatory drugs and renin-angiotensin system inhibitors (FDA, 2023a).
What is the clinical-trial update for Eskalith CR?
No current pivotal clinical-development program is centered on the Eskalith CR brand. The relevant clinical-trial activity concerns lithium carbonate, lithium salts or lithium as an investigational treatment in other diseases.
Bipolar disorder studies
Lithium remains an established treatment rather than a drug requiring a new registration trial for its original indication. Current research is concentrated on:
- relapse prevention and maintenance strategies;
- lithium response biomarkers;
- treatment-resistant bipolar disorder;
- suicide-risk reduction;
- comparisons with valproate, lamotrigine, quetiapine and other maintenance treatments;
- adherence and therapeutic drug monitoring.
These studies may generate new clinical evidence but generally do not create new patent protection for the Eskalith CR formulation.
Suicide-prevention research
Lithium is frequently studied for its potential association with reduced suicide risk in bipolar disorder and recurrent mood disorders. The evidence base includes randomized trials, observational studies and meta-analyses. The clinical question remains important, but suicide prevention is not a standalone FDA-approved Eskalith CR indication.
Neurodegenerative and other investigational uses
Lithium has also been studied in amyotrophic lateral sclerosis, Alzheimer’s disease, Huntington’s disease and other neurological conditions. Results have been mixed. Several programs have failed to establish a clear efficacy signal or have been limited by tolerability and trial-design problems. These studies have not created an approved new indication for Eskalith CR.
ClinicalTrials.gov lists lithium-related studies across psychiatry, neurology and other therapeutic areas, but trial activity should not be interpreted as branded Eskalith CR development (National Library of Medicine, 2024).
What is the FDA regulatory status of Eskalith CR?
The regulatory position is commercially weak for the brand and stable for the active ingredient.
FDA records and labeling databases identify Eskalith CR as a historical lithium carbonate controlled-release product. The brand is not the principal source of current US supply. Generic lithium carbonate extended-release tablets are marketed by multiple manufacturers, subject to abbreviated new drug applications and applicable FDA quality requirements.
The product’s regulatory relevance is therefore split:
- The original Eskalith CR approval establishes historical regulatory precedent for the controlled-release dosage form.
- Generic manufacturers rely on abbreviated approval pathways and must demonstrate pharmaceutical equivalence and bioequivalence.
- Current clinical demand is served through generic products rather than an active branded franchise.
Lithium carbonate extended-release products require careful substitution management because release characteristics, tablet strengths, dosing schedules and serum concentration profiles may differ between products. FDA-approved labeling remains the controlling source for product-specific administration and conversion instructions (FDA, 2023a; FDA, 2023b).
What is the Orange Book status of Eskalith CR?
The Orange Book is relevant mainly for historic approval and generic reference-product analysis. Eskalith CR does not have a commercially meaningful period of current Orange Book exclusivity.
| Orange Book issue |
Eskalith CR assessment |
| Active branded exclusivity |
None identified |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired or not commercially relevant |
| Current branded Paragraph IV barrier |
No material barrier identified |
| Generic competition |
Established |
| Relevant regulatory strategy |
ANDA-based generic substitution |
Any historical patents or exclusivities associated with lithium carbonate or the original controlled-release product have long since expired. The principal market question is therefore product availability and manufacturing consistency, not patent timing.
What patents protect Eskalith CR?
No active composition-of-matter patent protects lithium carbonate. Lithium carbonate is an old, well-characterized compound with extensive historical medical use.
Potential historical protection would have concerned:
- controlled-release tablet design;
- excipient composition;
- manufacturing processes;
- dissolution characteristics;
- dosing or conversion methods.
Those rights are either expired, abandoned or commercially immaterial. Current generic products may have formulation-specific patents or regulatory exclusivities in isolated cases, but those rights do not recreate Eskalith CR exclusivity.
How strong is the Eskalith CR patent estate?
The patent estate is weak from a commercial standpoint.
| Patent category |
Status |
| Active ingredient |
No meaningful protection |
| Original formulation |
Expired historical rights |
| Controlled-release technology |
Potentially relevant only to individual generic products |
| Method of treatment |
Broad lithium treatment claims are generally old and difficult to enforce |
| Manufacturing process |
Product-specific and unlikely to block the market |
| Brand-specific exclusivity |
None of material current value |
The absence of a live patent estate reduces litigation risk but also eliminates a conventional pathway for premium pricing or a protected reformulation strategy.
When did Eskalith CR lose exclusivity?
Eskalith CR lost meaningful US exclusivity years ago. The precise date depends on the historical NDA, patent listings and exclusivity records attached to the approved product. In practical terms, generic lithium carbonate products have been available for many years, and the current market is fully post-exclusivity.
The relevant commercial timeline is:
| Period |
Event |
| Historical launch period |
Eskalith CR introduced as a controlled-release lithium carbonate product |
| Generic entry period |
Generic lithium carbonate immediate-release and extended-release products entered after approval and patent expiry |
| Post-exclusivity period |
Multiple manufacturers supplied lithium carbonate products |
| Current period |
Brand has limited or no active commercial role; generic supply determines market access |
Which companies are challenging Eskalith CR?
No active branded Paragraph IV campaign is central to the Eskalith CR market. The competitive challenge occurred through the normal generic-entry process after expiration of historical rights.
The relevant competitors are manufacturers of generic lithium carbonate, including companies that have marketed immediate-release and extended-release tablets in the United States. Product availability can change because of discontinuations, manufacturing interruptions, FDA actions and wholesaler inventory conditions.
No biosimilar pathway applies. Lithium carbonate is a small-molecule drug, not a biologic. Generic competition proceeds through ANDA regulation rather than the Public Health Service Act biosimilar pathway.
What patent litigation affects Eskalith CR?
No major current patent litigation is associated with the Eskalith CR brand. Any historical disputes involving lithium carbonate formulations would have limited present-day relevance because the original product and its core technology are no longer protected by enforceable exclusivity.
Current legal risk is more likely to arise from:
- product liability claims involving lithium toxicity;
- manufacturing or quality-control disputes;
- shortages and supply obligations;
- labeling and medication-error issues;
- disputes involving specific generic formulations.
These risks differ from patent litigation and do not support a branded exclusivity strategy.
What formulation patents are relevant to extended-release lithium?
Extended-release lithium products can differ in tablet matrix, release profile, dissolution behavior and dosing instructions. Formulation patents may protect a particular excipient system or manufacturing process, but they do not generally prevent competition from products using different technologies.
The key technical barriers are regulatory and manufacturing rather than patent-based:
- reproducible lithium content;
- controlled dissolution across the intended release period;
- batch-to-batch uniformity;
- stability under storage conditions;
- bioequivalence to the reference product;
- prevention of medication errors during product substitution.
Lithium’s narrow therapeutic index increases the importance of product consistency. A manufacturer that introduces a new extended-release product must manage both FDA bioequivalence requirements and clinical concerns about switching and serum concentration monitoring.
What generic entry risks exist for Eskalith CR?
Generic-entry risk is already realized rather than prospective. The brand faces four principal commercial constraints:
- Generic substitution limits branded pricing.
- Prescribers and pharmacies can use lower-cost alternatives.
- Payers have little reason to reimburse a legacy brand at a premium.
- A new branded formulation would need a clinically meaningful advantage, such as improved tolerability, adherence or monitoring.
A relaunch would face additional hurdles. Lithium is inexpensive, familiar to clinicians and supported by extensive generic supply. A reformulated product would need to justify higher pricing through evidence that changes outcomes, safety or adherence.
What is the Eskalith CR market size and revenue exposure?
Public company filings generally do not report Eskalith CR revenue as a separate current product line. The brand’s direct revenue exposure is therefore immaterial relative to the broader lithium carbonate market.
The market should be divided into three segments:
| Segment |
Commercial outlook |
| Eskalith CR brand |
Minimal or no meaningful current revenue |
| Generic lithium carbonate immediate-release |
Mature, low-price market |
| Generic lithium carbonate extended-release |
Mature market with supply and substitution variability |
| New lithium formulations |
Niche opportunity requiring differentiation |
Lithium carbonate demand is supported by the long-term prevalence of bipolar disorder and continued guideline recognition of lithium as a maintenance option. Revenue growth is constrained by generic pricing, low unit costs and limited treatment expansion.
What is the market projection for Eskalith CR and lithium carbonate?
Eskalith CR brand projection
The most supportable projection is that Eskalith CR brand revenue remains negligible unless the product is relaunched under a new commercial owner. A conventional branded-growth forecast is not justified because the product lacks current exclusivity, differentiated clinical development and an established premium reimbursement position.
Generic lithium carbonate projection
The generic market should remain stable to modestly expanding in volume, with limited value growth. Main drivers include:
- long-term treatment of bipolar disorder;
- continued use in maintenance therapy;
- replacement of discontinued products;
- periodic supply shortages;
- growth in psychiatric diagnosis and treatment access.
Offsetting factors include generic price erosion, competing mood stabilizers, adherence limitations and renal or thyroid monitoring requirements.
Scenario framework
| Scenario |
Market implication |
| Base case |
Stable generic demand, low pricing and no meaningful Eskalith CR brand recovery |
| Upside case |
Higher lithium use from expanded maintenance treatment and improved adherence programs |
| Downside case |
Further generic price compression, supply interruptions or substitution by alternative mood stabilizers |
| Relaunch case |
Limited niche opportunity only if a sponsor offers clinically validated dosing, monitoring or tolerability advantages |
How does Eskalith CR compare with competing bipolar treatments?
Lithium competes with valproate, carbamazepine, lamotrigine and atypical antipsychotics. Its advantages include long clinical experience, maintenance efficacy and evidence supporting suicide-risk reduction in selected populations. Its disadvantages include serum-level monitoring, renal and thyroid toxicity, narrow therapeutic range and clinically important drug interactions.
| Treatment |
Main commercial position |
Key differentiation |
| Lithium carbonate |
Mature generic |
Long-term maintenance and established evidence |
| Valproate/divalproex |
Mature generic |
Mania treatment; reproductive and hepatic safety concerns |
| Lamotrigine |
Mature generic |
Bipolar depression and maintenance; limited acute mania utility |
| Quetiapine |
Generic and branded formulations |
Broad bipolar efficacy, including depressive episodes; sedation and metabolic risks |
| Lurasidone and other newer agents |
Higher-value branded or generic markets |
Bipolar depression and differentiated tolerability profiles |
Eskalith CR’s controlled-release format offers dosing convenience but does not by itself create a durable competitive advantage.
What licensing deals could affect Eskalith CR?
No major current licensing transaction is associated with Eskalith CR. A future deal would more likely involve:
- a generic supply agreement;
- a private-label extended-release lithium product;
- a digital adherence and monitoring platform;
- a reformulated lithium product;
- an international distribution arrangement.
The asset’s low price and lack of exclusivity reduce the economic rationale for a conventional brand licensing transaction. Commercial value would depend on supply reliability, regulatory rights and differentiated formulation technology rather than the Eskalith CR name.
What geographic markets remain relevant?
The United States is a mature generic market. International markets continue to use lithium carbonate and other lithium salts, but brand names, dosage forms, reference products and regulatory statuses vary by country.
Geographic opportunities are more likely to arise from:
- registration in markets with limited extended-release availability;
- reliable supply in shortage-prone regions;
- hospital and government procurement;
- local manufacturing;
- country-specific packaging and medication-monitoring requirements.
US patent expiry does not automatically determine freedom to operate elsewhere. Any international commercialization requires separate review of national patents, regulatory approvals, trademarks and local reference-product rules.
Key Takeaways
- Eskalith CR is a legacy extended-release lithium carbonate product with no meaningful current branded exclusivity.
- Clinical research continues on lithium, especially in bipolar maintenance, suicide prevention and neurological disease, but it is not centered on Eskalith CR.
- No biosimilar risk applies because lithium carbonate is a small molecule.
- Generic lithium carbonate products have already captured the market.
- The patent estate is commercially weak because composition, formulation and historical exclusivity rights are expired or immaterial.
- No major current Paragraph IV campaign or patent litigation drives the Eskalith CR market.
- Generic lithium carbonate demand should remain stable, but value growth is limited by low pricing.
- A commercial relaunch would require a differentiated formulation, better adherence, improved monitoring or a clinically demonstrated safety advantage.
FAQs About Eskalith CR
Is Eskalith CR still available in the United States?
Eskalith CR has limited or no meaningful branded availability. Generic lithium carbonate extended-release products are the principal US supply source.
Is Eskalith CR the same as Lithobid?
Both products contain extended-release lithium carbonate, but they are separate branded products with potentially different release characteristics, labeling and substitution considerations. Switching should follow product-specific prescribing information and serum lithium monitoring.
Can patients switch from Eskalith CR to generic lithium carbonate ER?
A switch may be possible, but the products should not be treated as automatically interchangeable in every clinical circumstance. Dose, formulation, administration schedule and serum lithium concentration should be reviewed.
Does Eskalith CR have an active composition-of-matter patent?
No. Lithium carbonate is an old active ingredient, and no current composition-of-matter patent provides meaningful exclusivity for Eskalith CR.
Could a new lithium formulation obtain FDA exclusivity?
Yes. A genuinely new formulation, delivery system or clinically differentiated product could potentially receive patent protection and regulatory exclusivity. The sponsor would need to establish a legally and clinically distinct product rather than rely on the historical Eskalith CR brand.
References
-
U.S. Food and Drug Administration. (2023a). Lithium carbonate extended-release tablets: Prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
National Library of Medicine. (2024). ClinicalTrials.gov: Studies involving lithium carbonate and lithium salts. https://clinicaltrials.gov
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
